Following the recommendations of the authorities for the coronavirus pandemic, SARA Pharm has taken the necessary measures to ensure the continuity of its activity. The current projects are on-going. The laboratory is operational and the necessary precautions have been taken to allow the safe reception of samples. We do not foresee any impact on our activity to date. In the event of an evolution, we will not fail to keep you informed.


SARA Pharm Solutions will participate in CPhI Worldwide in Barcelona, Spain, 4th-6th October, 2016.

Please contact us in order to arrange a meeting.

Sara Pharm scientists, together with University “Politehnica” of Bucharest, Faculty of Applied Chemistry and Material Science, “Ilie Murgulescu” Institute of Physical Chemistry, National Institute of Research and Development for Biological Sciences, Centre of Bioanalysis, National Institute of Materials Physics and the Center for Organic Chemistry C.D. Nenitescu managed to develop an efficient synthesis method for obtaining pure phase W2C at low temperatures (<1050 C),

through the carbothermal reduction of tungsten oxide species in the presence of metallic palladium nanoparticles obtained in situ. The resulting composite materials contain Pd(0) and W2C particles well-dispersed on carbon, with sizes between 50 and 500 nm, showing promise as as potential anode materials for the electro-oxidation of formic acid. The full paper can be accessed here:

This work was supported by the Romanian grant POSCCE O2.3.3.

  1. 1557/2011 (SARELCAT) carried out at Sara Pharm.

Sara Pharm Solutions scientists, together with University „Politehnica” of Bucharest, Faculty of Applied Chemistry and Materials Science, Chemical Engineering Department, managed to study m-xylene catalytic combustion in a laboratory set-up, over a commercial Pt/Alumina catalyst, using concentrations typical for depollution applications. The operating conditions consisted in temperatures within the interval 120-360 oC, hydrocarbon concentration in the range of 450-1300 ppmv and WHSW (volume flow rate to catalyst weight ratio) between 0.067 and 0.2 m3kg-1s-1. In these conditions was observed a negative reaction order in respect with the m-xylene, a total m-xylene combustion being obtained at temperatures above 250 oC. A power law kinetic model was found to adequately correlate the experimental data. More information is available at

Sara Pharm Solutions will attend Horizon 2020 Health Partnering Day 2016 in Brussels on July 7th, 2016.

Please contact us in order to arrange a meeting.

Sara Pharm Solutions scientists, together with University „Politehnica” of Bucharest, Faculty of Applied Chemistry and Materials Science, Chemical Engineering Department, managed to study the combustion kinetics of the cyclooctane and o-xylene, alone and in their binary mixture, have been experimentally investigated over a commercial Pt/γ-alumina catalyst. The studies were carried out in a laboratory set-up, with diluted hydrocarbon-air mixtures, typical for depollution applications. The experiments were conducted at atmospheric pressure and temperatures between 140 and 400 °C, hydrocarbons concentration 200–1000 ppmv and WHSW (mass flow rate to catalyst weight ratios) in the range 280–590 h−1. The results evidenced an important inhibition of cyclooctane combustion by the presence of o-xylene, throughout the working domain. Based on the experimental measurements and postulating surface mechanisms, rate expressions were developed for the combustion of the two hydrocarbons, in pure state and as binary mixtures. The cyclooctane was found to react by an Eley–Rideal type mechanism, whereas the o-xylene combustion was explained by a Langmuir-Hinshelwood scheme. More information is available at

SARA Pharm Solutions was approved by the National Agency for Medicine and Medical Devices for physico-chemical testing, stability testing,
method validation and development on API and final products, obtaining Good Manufacturing Practice (GMP) certification.

Approved testing activities:

1. Physicochemical testing:
XRPD – X-Ray Powder Diffraction;
DSC – Differential Scanning Calorimetry;
TGA – Thermogravimetric analysis;
HPLC – High- Performance Liquid Chromatography;
– melting point;
– freezing point;
– solubility;
– aspect and coloration of solutions;
– loss on drying;
– pH determination;
– water determination;
– potentiometric titration.

2. Stability testing: accelerated and long term conditions.

3. Development and validation of analytical methods.

You can view the authorization here.

Sara Pharm Solution has carried out an in-house research program towards the development of shape-stabilized phase change materials. Together with scientists from University “Politehnica” of Bucharest and the “Ilie Murgulescu” Institute of Physical Chemistry, our team developed new shape-stabilized materials with large heat of fusion values (up to 124 kJ/kg) and a theoretical model to help others design better such materials. You can read more in the Journal of Physical Chemistry C paper, at

SARA Pharm Solutions will attend Biotech Outsourcing Strategies cmc on 10th & 11th June 2015, in Hilton Munich Park, Munich, Germany.

Please contact us in order to arrange a meeting.

Sara Pharm Solutions scientists, together with Adaptive Supramolecular Nanosystems Group, IEM, Montpellier, France and the Center for Organic Chemistry, Romanian Academy, Bucharest, managed to compress single alkyl chains inside a self assembled crystalline nanocage. Thus, it was shown that alkyl chains cannot be used as nanosprings, as their compressed states are stabilized by dihydrogen contacts. Furthermore, the self assembly out of water of the nanocage provides insights in complex salt screenings and new drug delivery complexes. More information is available at:

In collaboration with University “Politehnica” Bucharest, Sara Pharm Solution scientists have implemented a knowledge-based, hydrogen bonding propensity model in order to quantify the hydrogen bonding strength between a cytostatic drug and inorganic or inorganic-organic drug delivery systems. Beside fundamental insight into the drug-counterion-carrier system, their efforts have yielded a new strategy for greatly improving the dissolution rate of poorly soluble drugs. More about this topic is available in the RSC Advances paper, found at .